FAK inhibition decreases hepatoblastoma survival both in vitro and in vivo

Translational Oncology

Volumn 6, Issue 2, 2013, Pages 206-215

  Gillory, Lauren A ^a   Stewart, Jerry E ^a   Megison, Michael L ^a   Nabers, Hugh C ^a   Mroczek Musulman, Elizabeth ^b   Beierle, Elizabeth A ^a  

^a University of Alabama at Birmingham   (United States)

^b Children's of Alabama ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4,5 BENZENETETRAAMINE TETRAHYDROCHLORIDE; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; PF 573228; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR XENOGRAFT;

EID: 84875799324     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12505     Document Type: Article

References (30)

1. Stocker JT (1994). Hepatoblastoma. Semin Diagn Pathol 11, 136-143.
2. Davies JQ, de la Hall PM, Kaschula RO, Sinclair-Smith CC, Hartley P, Rode H, and Millar AJ (2004). Hepatoblastoma-evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases. J Pediatr Surg 39, 1321-1327.
3. Xing A, Chen HC, Nowlen JK, Taylor SJ, Shalloway D, and Guan JL (1994). Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell 5, 14-21.
4. Chen HC and Guan JL (1994). Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 91, 10148-10152.
5. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S, and Xu L (2000). Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 6, 2417-2423.
6. Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, Cance WG, McGrady P, and London WB (2008). Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res 14, 3299-3305.
7. Han EK, McGonigal T, Wang J, Giranda VL, and Luo Y (2004). Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs. Anticancer Res 24, 3899-3905.
8. Xu L, Yang X, Bradham C, Brenner D, Baldwin AJ, Craven R, and Cance W (2000). The focal adhesion kinase suppresses transformation-associated, anchorageindependent apoptosis in human breast cancer cells. Involvement of death receptorrelated signaling pathways. J Biol Chem 275, 30597-30604.
9. Beierle E, Ma X, Trujillo A, Kurenova E, Cance W, and Golubovskaya V (2010). Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog 49, 224-234.
10. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, and Cance WG (2008). A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 51, 7405-7416.
11. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, and Golubovskaya VM (2009). A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 8, 2435-2443.
12. Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, CanceWG, and Golubovskaya VM (2010). Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 9, 1005-1015.
13. Chen JS, Huang XH, Wang Q, Chen XL, Fu XH, Tan HX, Zhang LJ, Li W, and Bi J (2010). FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis 27, 71-82.
14. Haid S, Windisch MP, Bartenschlager R, and Pietschmann T (2010). Mousespecific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol 84, 964-975.
15. Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, Ma X, Vella J, Cance WG, and Golubovskaya VM (2007). N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem 282, 12503-12516.
16. Golubovskaya VM and Cance WG (2007). Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 263, 103-153.
17. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, et al. (2007). Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282, 14845-14852.
18. Fujii T, Koshikawa K, Nomoto S, Okochi O, Kaneko T, Inoue S, Yatabe Y, Takeda S, and Nakao A (2004). Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol 41, 104-111.
19. Yuan Z, Zheng Q, Fan J, Ai KX, Chen J, and Huang XY (2010). Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma. J Cancer Res Clin Oncol 136, 1489-1496.
20. Hsiao CC, Kao YH, Huang SC, and Chuang JH (2012). TLR4 agonists inhibit migration and invasion of hepatoblastoma cells. Pediatr Blood Cancer 60, 248-253
21. Leaphart CL, Cavallo J, Gribar SC, Cetin S, Li J, Branca MF, Dubowski TD, Sodhi CP, and Hackam DJ (2007). A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol 179, 4808-4820.
22. Hartmann W, Küchler J, Koch A, Friedrichs N, Waha A, Endl E, Czerwitzki J, Metzger D, Steiner S, Wurst P, et al. (2008). Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 15, 4538-4545.
23. Wagner F, Henningsen B, Lederer C, Eichenmüller M, Gödeke J, Müller-Höcker J, Schweinitz DV, and Kappler R (2012). Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients. Eur J Cancer 48, 2442-2450.
24. Schnater JM, Bruder E, Bertschin S, Woodtli T, de Theije C, Pietsch T, Aronson DC, von Schweinitz D, Lamers WH, and Köhler ES (2006). Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice. J Hepatol 45, 377-386.
25. Turecková J, Vojtechová M, Krausová M, Sloncová E, and Korínek V (2009). Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells. Transl Oncol 2, 281-290.
26. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, and Tonghua L (2009). Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 21, 125.
27. Walsh MF, Thamilselvan V, Grotelueschen R, Farhana L, and Basson M (2003). Absence of adhesion triggers differential FAK and SAPKp38 signals in SW620 human colon cancer cells that may inhibit adhesiveness and lead to cell death. Cell Physiol Biochem 13, 135-146.
28. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, et al. (2008). Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68, 1935-1944.
29. Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, Shyr Y, Estrada L, et al. (2010). DNA copy number aberrations in smallcell lung cancer reveal activation of the focal adhesion pathway. Oncogene 29, 6331-6342.
30. Dewerth A, Wonner T, Lieber J, Ellerkamp V, Warmann SW, Fuchs J, and Armeanu-Ebinger S (2012). In vitro evaluation of the Aurora kinase inhibitor VX-680 for hepatoblastoma. Pediatr Surg Int 28, 579-589.